CNR1 and type 2 diabetes mellitus: This study represented evidence that the beneficial metabolic effects of CB1 inverse agonists can be achieved in humans, and was followed by several other successful phase III trials with Rimonabant and other compounds in the same class in obese subjects with dyslipidaemia or type 2 diabetes.